Esophagogastric Cancer Clinical Trial
Official title:
Pilot Study of Dental Erosion as a Non-invasive Biomarker of Esophagogastric Cancer
NCT number | NCT05612048 |
Other study ID # | 22-370 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | November 3, 2022 |
Est. completion date | November 2025 |
The researchers are doing this study to find out more about what may lead to the loss of tooth enamel (the thin outer covering of the tooth) and how often it happens in people with esophagogastric cancer, colorectal cancer, pancreatic cancer, breast cancer, head and neck cancer, or non-small cell lung cancer, or a healthy volunteer.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | November 2025 |
Est. primary completion date | November 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject is willing and able to provide written informed consent. - Patients with a history of esophagogastric, HNSCC, PDAC, CRC, or NSCLC or healthy controls - Patients must be able to fully comprehend and complete the survey and be willing to have pictures taken of their teeth with a camera or intra-oral camera. - Patients must be able to understand English language or have access to adequate translation services. - Age = 18 years old. Exclusion Criteria: - Subjects without evaluable molars or with significant molar dental work precluding dentists from assessing enamel status, Note: evaluable is defined as having bilateral assessable mandibular molars, or erosions present in the remaining assessable quadrants. - For healthy controls only, patients cannot have a non-skin cancer history nor presenting for a procedure evaluating reflux symptoms. |
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence of dental erosions | scored with a modified BEWE index. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
Completed |
NCT04161781 -
A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
|
||
Completed |
NCT01803282 -
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05796102 -
PET-MRI Esophagus Feasibility Study
|
N/A | |
Recruiting |
NCT04656041 -
Folfox+Irinotecan+Chemort In Esophageal Cancer
|
Phase 2 | |
Withdrawn |
NCT02296671 -
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
|
Phase 2 | |
Active, not recruiting |
NCT04757363 -
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
|
Phase 2 | |
Completed |
NCT02023996 -
PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
|
N/A | |
Recruiting |
NCT05117931 -
A Study of Amivantamab in People With Esophagogastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT03760289 -
DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer
|
Phase 2 | |
Completed |
NCT01167114 -
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03133650 -
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
|
Phase 1 |